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Abstract
Background: Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of 
hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or 
with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our 
study was to describe our use of low-dose fenoldopam (0.03-0.09 μg/kg/min) infusion in critically ill burn patients with 
AKI.
Methods: We performed a retrospective analysis of consecutive patients admitted to our burn intensive care unit 
(BICU) with severe burns from November 2005 through September 2008 who received low-dose fenoldopam. Data 
obtained included systolic blood pressure, serum creatinine, vasoactive medication use, urine output, and intravenous 
fluid. Patients on concomitant continuous renal replacement therapy were excluded. Modified inotrope score and 
vasopressor dependency index were calculated. One-way analysis of variance with repeated measures, Wilcoxson 
signed rank, and chi-square tests were used. Differences were deemed significant at p < 0.05.
Results: Seventy-seven patients were treated with low-dose fenoldopam out of 758 BICU admissions (10%). Twenty 
(26%) were AKI network (AKIN) stage 1, 14 (18%) were AKIN stage 2, 42 (55%) were AKIN stage 3, and 1 (1%) was AKIN 
stage 0. Serum creatinine improved over the first 24 hours and continued to improve through 48 hours (p < 0.05). There 
was an increase in systolic blood pressure in the first 24 hours that was sustained through 48 hours after initiation of 
fenoldopam (p < 0.05). Urine output increased after initiation of fenoldopam without an increase in intravenous fluid 
requirement (p < 0.05; p = NS). Modified inotrope score and vasopressor dependency index both decreased over 48 
hours (p < 0.0001; p = 0.0012).
Conclusions: These findings suggest that renal function was preserved and that urine output improved without a 
decrease in systolic blood pressure, increase in vasoactive medication use, or an increase in resuscitation requirement 
in patients treated with low-dose fenoldopam. A randomized controlled trial is required to establish the efficacy of low-
dose fenoldopam in critically ill burn patients with AKI.
Background
Fenoldopam mesylate is a highly selective dopamine-1
receptor agonist approved for the treatment of hyperten-
sive emergencies that may have a role at low doses in pre-
serving renal function in those at high risk for or with
acute kidney injury (AKI) [1]. Historically, non-selective
dopaminergic stimulants have been of mixed benefit as
the improvement in renal vascular resistance, glomerular
filtration rate (GFR), and sodium excretion has been
counterbalanced by hypotension and arrhythmias [2].
Because fenoldopam is a pure dopamine A-1 agonist, it
a l l o w s  a  m o r e  t a r g e t e d  a p p r o a c h  t o  m a n i p u l a t e  r e n a l
hemodynamics while minimizing systemic symptoms [3].
Its renal effects include decreased renal vascular resis-
tance, increased GFR, increased natriuresis through inhi-
bition of the Na/H exchanger and Na/K/ATPase-
mediated sodium reabsorption in the proximal tubules,
and water diuresis via the inhibition of antidiuretic hor-
mone (ADH). For treatment of AKI, fenoldopam is postu-
lated to work by restoring renal blood flow (RBF) via non-
nitric oxide mediated arterial dilation [4].
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Fenoldopam was initially indicated for augmentation of
RBF during treatment for hypertensive emergency. Its use
is associated with a dose-dependent (up to 0.5 mcg/kg/
min) antihypertensive effect and increased RBF [5,6].
Subsequent studies have attempted to exploit fenoldo-
pam effect on RBF with varying degrees of success. The
literature does not clearly indicate a reduction in con-
trast-induced nephropathy in cardiovascular surgery
patients although most of the studies indicate either a
decrease in renal failure or a minimization of AKI [7-15].
Some studies show a benefit primarily in non-diabetic
patients, whereas others show the opposite [16,17].
Fenoldopam use is also being evaluated in the high-risk
pediatric population as a diuretic and anti-hypertensive
[18,19]. A recent meta-analysis suggests a reduction in
the need for renal replacement therapy and mortality in
patients with AKI and fenoldopam use [20].
AKI is associated with increased morbidity and mortal-
ity in medical, surgical, and BICU patients [21-27]. Addi-
tionally, aggressive treatment has been shown to improve
mortality in the burn population [28,29].
Concern remains regarding fenoldopam's antihyperten-
sive effect. Fenoldopam has been associated with
hypotension, tachycardia, congestive heart failure, myo-
cardial infarction, and hypokalemia. Care should be taken
when considering using fenoldopam in patients on beta
bl oc k e rs  a nd diur et i cs  as  t his  m a y  incr ease  t he  ris k of
hypotension and hypokalemia.
There are no data on fenoldopam use in the burn popu-
lation. Therefore, the purpose of our study was to
describe our use of low-dose fenoldopam (0.03-0.09 μg/
kg/min) infusion in critically ill burn patients with AKI.
Methods
A retrospective review of consecutive patients admitted
to our BICU was approved by the local institutional
review board. The database includes all patients admitted
to the BICU with burns from November 2005 to Septem-
ber 2008 who received low-dose fenoldopam.
Initiation of fenoldopam infusion was at the discretion
of the attending physician, but criteria typically used were
low urine output despite adequate resuscitation or rising
serum creatinine. Discontinuing the infusion was like-
wise at the discretion of the attending physician. Usual
end-points were resolution of serum creatinine elevation,
normalization of physiology, and restoration of urine out-
put. In general, we dose fenoldopam infusion at 0.09 μg/
kg/min and wean off when there is resolution of AKI as
evidenced by SCr returning to baseline.
Data were obtained from the COLLECTOR database
and the patient's electronic medical record. The COL-
L E C T O R  d a t a b a s e  i s  m a i n t a i n e d  b y  t h e  U n i t e d  S t a t e s
Army Institute of Surgical Research (USAISR) and con-
tains detailed demographic, laboratory, and treatment
information on all patients admitted to the BICU. A ret-
rospective analysis was conducted of patients who
received low-dose fenoldopam and were admitted to the
BICU. Patients were excluded if their mechanism was
other than thermal burn or if they received any form of
renal replacement therapy.
Demographic, laboratory, and physiologic data were
obtained and outcomes determined. Data compiled for
analysis included demographic data, admission vital
signs, admission laboratory tests, injury severity scale
(ISS) scores, and mortality. Vital signs and laboratory
tests taken on admission were systolic blood pressure
(SBP), diastolic blood pressure (DBP), pulse, temperature
(ºF), blood urea nitrogen (BUN), and serum creatinine
(SCr). Recorded vital signs and compiled laboratory
results were the earliest available after admission. Addi-
tionally, SCr, SBP, DBP, vasoactive medication use, intra-
venous fluid (IVF) requirement, and urine output (UOP)
were measured serially prior to initiation of fenoldopam.
The only vasoactive medications utilized included nor-
epinephrine, dobutamine, and vasopressin. The dose of
vasoactive agents is expressed as the modified inotropic
score, a dimensionless variable calculated as (dobutamine
dose × 1) + (norepinephrine dose × 100) + (vasopressin
dose × 100), wherein dobutamine and norepinephrine
doses are expressed as μg/kg/min and vasopressin dose is
expressed as units/min [30-33]. A dose-response rela-
tionship between vasoactive medication dose and mean
arterial pressure (MAP) was used as another surrogate
measure for the degree of hemodynamic impairment.
This relationship is expressed as the vasopressor depen-
dency index, which is the ratio of modified inotropic score
to MAP; the higher the index, the more dependent the
patient is on vasoactive medications [34].
A chart review was performed to determine which
patients had a possible diagnosis of concurrent sepsis.
Patients were also classified by the AKI Network (AKIN)
scoring criteria [27]. AKIN stage was determined at the
time of initiation of fenoldopam using the lowest SCr
during admission as baseline.
Individual ISS scores were calculated from patient
medical records according to published guidelines
[35,36].
Microsoft Office Excel 2003 (Microsoft Corp, Red-
mond, WA) was used for database construction. Serial
measurements were compared with one-way analysis of
variance (ANOVA) with repeated measures and Wilcox-
son signed rank test. Categorical variables were described
with chi-square analysis using SPSS 16.0 (Cary, NC).
Variables are expressed as median with intraquartile
range or mean and standard deviation, and statistical sig-
nificance was set at a p value of less than 0.05.
Results
Between November 2005 and September 2008, 758
patients were admitted to the BICU. Of these, 77 patientsSimmons et al. BMC Anesthesiology 2010, 10:9
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(10%) were treated with low-dose fenoldopam. Patient
demographics are displayed in Table 1. Patients were
stratified by AKIN criteria and their mortality rates are
presented in Table 2. 5/77 (6%) received fenoldopam
within 24 hours of admission and 24/77 (31%) received
fenoldopam within 48 hours of admission. SCr improved
over the first 24 hours and continued to improve through
48 hours (Figure 1). SBP increased in the first 24 hours
and was sustained through 48 hours after initiation of
fenoldopam (Figure 2). Mean arterial pressure increased
over the first 24 hours and this increase was sustained at
48 hours after initiation of fenoldopam (76 ± 16 vs. 81 ±
15 vs. 81 ± 15; p < 0.05).
Upon initiation of fenoldopam in our study population,
9% (7/77) were on vasopressin alone, 3% (2/77) were on
norepinephrine alone, 6% (5/77) were on dobutamine
alone, and 8% (6/77) were on a combination of the three.
The modified inotrope score and the vasopressor depen-
dency index both decreased over 48 hours by one-way
ANOVA with repeated measures (p < 0.0001, p = 0.0012)
(Figures 3 and 4).
Scr improved at 24 hours and continued to improve at
48 hours in all AKIN stages when patients were stratified
by stage (Table 3). UOP increased after initiation of
fenoldopam without an associated increase in IVF. UOP
was significantly increased in the 12 hours after initiation
of fenoldopam overall and in stratified AKIN stages 2 and
3 patients (Table 4). IVF was not different pre- and post-
fenoldopam initiation overall and when stratified by stage
(Table 5). Overall mortality for our cohort was 38% (29/
77).
Discussion
Our retrospective study of low-dose fenoldopam to treat
AKI in critically ill burn patients demonstrated an
improvement in multiple markers of renal function
within the first 48 hours of therapy. These positive
changes included a decrease in SCr, an increase in UOP,
and decrease in the modified inotrope score and vaso-
pressor dependency index with essentially no change in
IVF administration. The use of fenoldopam in this study
appeared safe, without the hypotensive complications
that have historically been associated with this medica-
tion. To our knowledge, this study is the first to describe
the use of fenoldopam for AKI in the burn population.
Improvement in renal function occurred in the group
as a whole and within each subgroup when they were
broken down by AKI severity. This result suggests that
patients with all stages of AKI may benefit from the
increased RBF afforded by fenoldopam infusion. The
improvement in SCr was 26% for those with AKIN stage
1, 31% for AKIN stage 2, and 18% for AKIN stage 3. The
smaller improvement in AKIN stage 1 compared to stage
2 likely reflects a lower specificity for AKI by using the
new staging criteria for stage 1 so that some patients
without true AKI may have been included in the study
[27,37,38]. Additionally, the relatively low initial SCr in
patients with AKIN stage 1 limited the percentage of
improvement that could be demonstrated in this group.
Though still demonstrating benefit, the smallest percent-
age of improvement was seen in those patients with
AKIN stage 3. The limited response in this group proba-
Table 1: Patient Demographics
n = 77 Mean (SE) Median (IQR)
Age (yr) 42 (2) 37 (24-57)
ISS 28 (2) 25 (16-34)
TBSA (%) 42 (3) 40 (23-58)
Vent Days 35 (4) 21 (7-55)
ICU Days 56 (6) 45 (18-72)
Hospital Days 79 (8) 63 (31-100)
Inhalation Injury 28%
Concurrent Sepsis 60%
Table 2: AKI and Mortality by Stage
n (%) Mortality n(%)
All 77 (100%) 29 (38%)
AKI 76 (99%) 29 (38%)
Stage 1 20 (26%) 9 (45%)
Stage 2 14 (18%) 3 (21%)
Stage 3 42 (55%) 17 (40%)
Patients stratified by the Acute Kidney Injury Network 
classification system
Figure 1 Serum creatinine (SCr) over time following the initiation 
of fenoldopam. SCr improved over the first 24 hours and continued to 
improve at 48 hours after fenoldopam initiation. Data presented as 
mean with standard error.Simmons et al. BMC Anesthesiology 2010, 10:9
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bly reflects more severe underlying damage that has
moved beyond mere ischemia and is no longer corrected
with renal vasodilation.
Volume regulation is accepted as a critical aspect of
resuscitation of the burn patient. UOP is generally uti-
lized as one of the most consistent physiologic indicators
of adequate renal perfusion and resuscitation in the burn
population. Conversely, oliguria is generally accepted as a
sign of inadequate renal perfusion and resuscitation. Any
treatment strategy able to improve UOP while minimiz-
ing undesired effects deserves our consideration. Our use
o f  f e n o l d o p a m  w a s  a s s o c i a t e d  w i t h  a  5 0 %  i n c r e a s e  i n
UOP in the first 12 hours after initiation. This improve-
ment was seen in the group as a whole, as well as in AKIN
stage 2 and stage 3 patients. While not achieving statisti-
cal significance, there was also a trend towards increasing
urine output in patients classified as AKIN stage 1. The
observed improvement in urine output can be attributed
to fenoldopam based upon two separate facts: no signifi-
cant change in the volume of intravenous fluid infused
and a decrease in vasopressor requirements in the 48
hours following initiation of fenoldopam.
Given the mechanism of fenoldopam, early administra-
tion of the medication in the treatment and prevention of
AKI may be beneficial. During the early phases of acute
tubular necrosis (ATN), renal nerve stimulation, angio-
tensin II, thromboxane-A2, and endothelin lead to vaso-
constriction [39,38-43]. RBF is dependent on renal
vascular resistance (RVR) and systemic vascular resis-
tance (SVR), such that if RVR increases relative to the
S V R ,  R B F  w i l l  d e c r e a s e  [ 4 4 ]  R B F  h a s  b e e n  s h o w n  t o
decrease during the first 24 hours of ATN, and the kidney
loses its ability to autoregulate, such that during the first
12 to 24 hours of AKI, there is a direct relationship
between renal perfusion pressure (RPP) and RBF [45-47].
More specifically, it is the renal outer medullary blood
flow that is decreased, at least partially, secondary to cel-
lular detachment and luminal occlusion [48].
Prior work has demonstrated that in post-ischemic
AKI, nitric oxide synthase (NOS) activity is maximal at
baseline and cannot be increased further by other stimuli
of NOS activity [4]. Therefore, attempting to increase
RBF via nitric oxide-dependent vasodilators may prove
unsuccessful [4,49]. Given fenoldopam's nitric oxide
independent mechanism of action and its preferential
corticomedullary blood flow augmentation and ability to
increase oxygenation, it is conceivable that it provides
Figure 2 Systolic blood pressure over time following the initia-
tion of fenoldopam. Systolic blood pressure increased during the ini-
tial 24 hours after fenoldopam initiation. This increase was maintained 
at 48 hours. Data are presented as mean with standard error.
Figure 3 Modified inotrope score over time following the initia-
tion of fenoldopam. The modified inotrope score decreased over 48 
hours by one-way ANOVA with repeated measures. This change be-
came significant at 24 hours. p = 0.0001 and p = 0.004 respectively. 
Data presented as mean with standard error.
 
Figure 4 Vasopressor dependency index over time following the 
initiation of fenoldopam. The vasopressor dependency index de-
creased over 48 hours by one-way ANOVA with repeated measures. 
This change became significant at 48 hours. p = 0.0012 and p = 0.02 re-
spectively. Data presented as mean with standard error.
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additional RBF benefits over other commonly used vaso-
dilators such as nitroprusside [50-52].
Several authors have pointed out potential pitfalls with
the use of fenoldopam, including the potential for isch-
emia reperfusion injury secondary to the increased pro-
duction of reactive oxygen species [49,53,54].
Additionally, given the risk of hypotension inherent with
the use of fenoldopam, subsequent renal hypoperfusion is
a conceivable side effect [55]. However, our patients expe-
rienced an actual improvement in their UOP and a
decrease in their SCr, arguing against the presence of
renal ischemia reperfusion injury. Furthermore, there
was not an increased incidence of hypotension or in the
patient's fluid requirements, and there was a decrease in
the use of vasoactive medications. Moreover, Kien et al.
demonstrated that despite a MAP of < 60 mm Hg, both
cortical and medullary blood flow were increased by 30%
and 40%, respectively, with the use of fenoldopam, sug-
gesting that fenoldopam prevents the redistribution of
blood away from these critical regions during conditions
that can lead to AKI [51].
Our study has the inherent weaknesses of all retrospec-
tive studies. We were limited by the data available as well
as the lack of an appropriate control group to compare
our findings against. The study was not adequately pow-
ered to determine more clinically significant end points
s u c h  a s  r a t e  o f  d i a l y s i s  r e q u i r e m e n t ,  h o s p i t a l  o r  I C U
length of stay, differences based on etiology of renal dys-
f u n c t i o n ,  o r  m o r t a l i t y .  W e  a l s o  e x c l u d e d  p a t i e n t s  w h o
received renal replacement therapy. Renal replacement
therapy artificially lowers the serum creatinine and alters
the body's physiology such that gross measures of resus-
citation and renal physiology would not be applicable (i.e.
IVF, UOP, SCr). This limited the number of patients avail-
able for our study. Additionally, although most patients
likely had ischemic ATN as the etiology of their AKI,
there is potential that other etiologies such as nephro-
toxic ATN could have contributed to their AKI.
Conclusions
We have demonstrated that low-dose fenoldopam was
associated with an improvement in renal function and
UOP not related to additional volume resuscitation.
Additionally, there is no evidence, in our population, that
low-dose fenoldopam was associated with adverse hemo-
dynamic effects. Given the high morbidity and mortality
associated with AKI in this population, even marginal
improvements in SCr and UOP may translate into more
meaningful outcomes. It is clear that a safe, well-tolerated
modality is needed to prevent and treat AKI. A random-
ized controlled trial is required to see whether low-dose
fenoldopam can serve as that modality in critically ill
burn patients with AKI.
The key messages resulting from our retrospective
study are as follows:
- Fenoldopam is associated with improved hemody-
namics and increased UOP.
- Improvements are not associated with increased 
resuscitation or vasoactive medication requirements.
- Fenoldopam appears to be a safe adjunct in the 
treatment of AKI in burned patients.
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